Log in

Relevant bibliographies by topics / Hepatitis B – Social aspects / Journal articles

To see the other types of publications on this topic, follow the link: Hepatitis B – Social aspects.

Journal articles on the topic 'Hepatitis B – Social aspects'

Author: Grafiati

Published: 4 June 2021

Last updated: 9 February 2022

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the top 50 journal articles for your research on the topic 'Hepatitis B – Social aspects.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Browse journal articles on a wide variety of disciplines and organise your bibliography correctly.

1

Kosagovskaya, I. I., and E. V. Volchkova. "THE MEDICO-SOCIAL ASPECTS OF VIRAL HEPATITIDES WITH THE PARENTERAL WAY OF TRANSMISSION." Epidemiology and Infectious Diseases 18, no. 1 (February 15, 2013): 28–39. http://dx.doi.org/10.17816/eid40715.

Full text

Abstract:

The article is devoted to current epidemiological, social and economic aspects of parenteral viral hepatitis B and C. Statistical data on the incidence, prevalence, outcomes for viral hepatitides are provided. Prior medical and social factors influencing the formation of the epidemiological situation and the activity of infection with viral hepatitis B and C, including gaining the importance of the prevalence of parenterally transmitted viral hepatitis among drinkers, drug users, and HIV infected cases have been analyzed. The issues of economic losses and economic costs required to treat patients with viral hepatitis at various stages of infection were exhaustively covered. On the base of international recommendations a list of medical and social activities for prevention of chronic viral hepatitis B and C was given, the ways to reduce the prevalence of these socially significant diseases were proposed.

APA, Harvard, Vancouver, ISO, and other styles

2

Baramzina, Svetlana V. "VACCINE PREVENTION OF HEPATITIS B IN ADULTS: SOCIAL ASPECTS OF THE LACK OF ITS EFFICACY." Hygiene and sanitation 96, no. 6 (March 27, 2019): 508–15. http://dx.doi.org/10.18821/0016-9900-2017-96-6-508-515.

Full text

Abstract:

In Russia and the Kirov region (KR) there was a tendency to the reduction of the incidence rate of chronic hepatitis B (CHB) in adults due to vaccine prevention. Objective is to study the impact of the additional vaccination of adults from HBV-infection in 2007-2014 on the incidence rate of chronic hepatitis B on the example of the Kirov region; to assess the level of awareness of the “naive” population concerning epidemiology, outcomes and vaccine prevention of hepatitis B in the total group and in dependence on the age. Material and Methods. We treated data of Federal Supervision Service for Consumer’s Rights Protection and Human Welfare in the Russian Federation and KR on infectious diseases for the period of 1999-2014; State report on sanitary and epidemiological situation in the Russian Federation for 1998-2014, in the KR - for 2006-2014. With the help of the original questionnaire 850 persons aged of from 16 to 80 years, resided in the city of Kirov and the Kirov region, were interviewed anonymously, in 2013-15. Out of them for the comparison there were selected 2 groups: Group 1: cases aged of 18-35 years; Group 2: persons aged of 36-59 years. Results. The reason for the slow decrease in the incidence rate of chronic hepatitis B may be poor (20.3-64%) adult immunization coverage in 2007-2012. Poll “naive” adults revealed insufficient knowledge of epidemiology and outcomes of chronic hepatitis B, a good - questions vaccination of hepatitis B (81.8%). The survey of “naive” adults revealed the level of knowledge of the epidemiology and outcomes of HBV to be insufficient, the level concerning questions of vaccine prophylaxis for HBV to be good (81.8%). Awareness of HBV-infection depended on the age. Participants from the 2nd group had higher levels of general education. They knew ways of hepatitis B virus transmission significantly better but less about adverse outcomes of hepatitis B (11.0% cases) if compared with those of group 1, they showed more negative attitude to vaccination (30.8%) and failed to anticipate the possibility of antiviral therapy of Hepatitis B (27.7%). Conclusion. The lack of awareness on the epidemiology and outcomes of hepatitis B can be one of the reasons for the refusal of vaccination in persons aged of 36-59 years. The medical community must actualize the problem of HBV-infection for promotion of immunization coverage and achieving of inoculations coverage up to 80-90%.

APA, Harvard, Vancouver, ISO, and other styles

3

De Farias, Cleilton Sampaio, Ricardo Antunes Dantas de Oliveira, and Maurício R. M. P. da Luz. "O mapa das hepatites virais no Acre: entre territórios e territorialidades." Revista Brasileira de Geografia Física 12, no. 6 (January 30, 2020): 2339. http://dx.doi.org/10.26848/rbgf.v12.6.p2339-2354.

Full text

Abstract:

As hepatites virais são doenças causadas por vírus distintos (A, B, C e D), que têm em comum o acometimento particularmente forte do fígado humano. Objetivou-se mapear a distribuição das hepatites virais no Acre, no período de 2010 a 2014, por meio de dois indicadores. Esse mapeamento foi associado a proposições para explicar seus territórios, suas territorialidades e suas territorializações, sendo respectivamente os locais de maior ocorrência, as relações históricas e sociais que causaram essas enfermidades e a formação desses territórios. Em vista de tudo isto, as hepatites virais se territorializaram historicamente no Acre, possivelmente favorecidas por aspectos inadequados de vigilância epidemiológica, ligados com o controle de outras endemias que assolavam os municípios. Estes fatores, associados com as condições socioeconômicas e ambientais, com a desigualdade de renda, de escolaridade e de desenvolvimento humano desses espaços, permitiram que as relações que proporcionam a infecção e a transmissão dessas doenças fossem passadas de geração para geração. Esse processo resultou em territórios que apresentam, além de muitos casos notificados altas taxas de incidências como em Cruzeiro do Sul, Rio Branco, Tarauacá e Assis Brasil. The map of viral hepatitis in Acre: between territories and territorialities A B S T R A C TViral hepatitis are diseases caused by distinct viruses (A, B, C and D), which have in common the particularly strong involvement of the human liver. The objective of this study was to map the distribution of viral hepatitis in Acre between 2010 and 2014, using two indicators. This mapping was associated with propositions to explain their territories, their territorialities and their territorializations, being respectively the places of greatest occurrence, the historical and social relations that caused these diseases and the formation of these territories. In view of all this, viral hepatitis were historically territorialized in Acre, possibly favored by inadequate aspects of epidemiological surveillance, linked to the control of other endemic diseases that devastated the municipalities. These factors, associated with socioeconomic and environmental conditions, income inequality, schooling and human development of these spaces, allowed the relations that provide the infection and the transmission of these diseases were passed from generation to generation. This process resulted in territories that have, in addition to many cases reported high incidence rates such as Cruzeiro do Sul, Rio Branco, Tarauacá and Assis Brasil.Keywords: Viral hepatitis, Map, Territories, Acre.

APA, Harvard, Vancouver, ISO, and other styles

4

Santilli, Cecilia. "Ethnography of the socio-sanitary reception in Rome. How are HIV/AIDS and hepatitis b involved in creating the construction of legal categories assigned to migrants?" International Journal of Migration, Health and Social Care 17, no. 2 (March 1, 2021): 142–54. http://dx.doi.org/10.1108/ijmhsc-07-2019-0061.

Full text

Abstract:

Purpose This paper aims to investigate the role that Italian third sector organizations have in the process of social and administrative categorization of newly arrived migrants living with human immunodeficiency virus/acquired immunodeficiency syndrome (HIV/Aids) or hepatitis b. In Italy, free access to health is provided to all migrants and residence permits for medical treatment is granted for migrants living with a “serious illness” since the 1990s. The case of HIV/Aids and hepatitis b shows how this political openness, however, clashes with the tightening of migration policies. Design/methodology/approach The study is based on ethnographic research conducted between 2014 and 2016 within an associative centre that deals with the socio-health care of newly arrived migrants in Rome. In addition to the participant observations, the study is based in semi-structured interviews conducted with 10 health-care providers (nurses, health-care assistants and socio-cultural mediators) and doctors and with 22 migrants coming from Sub-Saharan Africa and living with HIV/AIDS (10) and hepatitis b (12). Findings In Italy, the two infections have been identified as top diseases among migrant populations in the country but if HIV/Aids is always considered as a “serious illness”, hepatitis b is considered as a public health priority only in the case of a treatment prescription. These aspects have an important impact on the interactions between medical and social professionals and migrants affected by HIV/AIDS and hepatitis b, contributing differently to the creation of legal categories assigned to migrants. Originality/value The case of HIV/Aids and hepatitis b shows how the political openness of the public health system, clashes with the tightening of migration policies and analyse the role of the third sector has in this issue.

APA, Harvard, Vancouver, ISO, and other styles

5

Raduto, O. I. "Medical social factors affecting the effectiveness of the treatment of viral hepatitis patients." Epidemiology and Infectious Diseases 19, no. 5 (October 15, 2014): 32–36. http://dx.doi.org/10.17816/eid40836.

Full text

Abstract:

There was performed the analysis of modern epidemiological, social and financial aspects of the hepatitis C treatment. There was considered the influence of some factors on the efficacy of the treatment efficacy, in particular, the genetic status of patients, stage of the disease, the development of side effects and patient compliance with the treatment regimen. Social factors were shown to include also the patient's race, language barriers, being in prison, availability of the treatment. The effectiveness of treatment for this group ofpatients is also influenced by the gender, young age, the presence of mental illness in the patient, drug and alcohol abuse. Financial constraints contribute to the reducing the commitment of the drugs intaking, the deterioration of the health status of viral hepatitis C and B patients, respectively, higher total health expenditure for the health care. There was made a conclusion about the necessity of the work on the formation of the adherence of this category of patients to the treatment, the patient and doctor must work together to make a treatment decision, after careful discussion of the need to comply treatment and risks of side effects, as well as re-infection.

APA, Harvard, Vancouver, ISO, and other styles

6

Mezzaroma, Ivano, Gianpiero D'Offizi, Elena Pinter, Rosetta Ferrara, Rosamaria Rosso, Emma Guerra, Giovanni Ricci, Maria Carta, Silvia Angelini, and Fernando Aiuti. "Immunological, Clinical and Epidemiological Aspects of an HIV-1 Positive Drug Abuser Cohort." Journal of Drug Issues 24, no. 4 (October 1994): 657–72. http://dx.doi.org/10.1177/002204269402400407.

Full text

Abstract:

We analyzed a cohort of intravenous drug abusers with HIV-1 disease attending our institute in the years 1985–1993. We focused particular attention on the epidemiological analysis of patients, and their clinical, immunological and infectious conditions. The significance of biological markers, particulary CD4+ lymphocyte count and the occurence of other viral infections such as Cytomegalovirus, Epstein-Barr virus, Herpes Simplex virus and Hepatitis B and C viruses in the progress of HIV-1 disease were evaluated. At least two-thirds of the patients at different stages of HIV-1 were treated with antiretroviral drugs: zidovudine (AZT) from 1987 up to the present and more recently didanosine (DDI) alone or in combination with AZT. Psychological and behavioral aspects of our HIV-1 infected drug abusers, in particular needle exchange and condom use, were analyzed.

APA, Harvard, Vancouver, ISO, and other styles

7

Poll, R. "Managing the public health risk of a 'sex worker' with hepatitis B infection: legal and ethical considerations." Journal of Medical Ethics 37, no. 10 (May 5, 2011): 623–26. http://dx.doi.org/10.1136/jme.2010.041293.

Full text

APA, Harvard, Vancouver, ISO, and other styles

8

Ayeni, Olubimpe A., Olubukunola O. Ayeni, and Robert Jackson. "Observations on the Procedural Aspects and Health Effects of Scarification in Sub-Saharan Africa." Journal of Cutaneous Medicine and Surgery 11, no. 6 (November 2007): 217–21. http://dx.doi.org/10.2310/7750.2007.00026.

Full text

Abstract:

Background: Scarification involves cutting or making an incision into the skin and then allowing the wound to heal, leaving a permanent scar. The purpose of this article is to examine the origins of scarification and its social and medical significance in sub-Saharan Africa. Methods: We conducted a computerized search in the MEDLINE electronic database with combinations of the following terms: scarification, tribal marks, keloid, hypertrophic scar, Africa, and sub-Saharan Africa. Inclusion criteria were studies published in English involving human participants. We reviewed the bibliography of each article that met our inclusion criteria for additional relevant studies. We abstracted data on the historical, social, and medical aspects of scarification from eligible studies. Results: This review of scarification in sub-Saharan Africa highlights the complex interplay that exists between biology and society. Photographs, artwork, and literary descriptions reveal that scarification results in hypertrophic or atrophic scars, although these types of scars are often mistakenly referred to as keloids. In terms of the procedural aspects of scarification, specific tools and substances were consistently used by various ethnic groups. Although much is known about the history of scarification as a form of identification in Africa, it appears that the practice also had medical applications. Scarification was used to treat conditions such as epilepsy, although it was also known to exacerbate conditions such as sarcoidosis, lichen planus, and psoriasis. Evolving cultural beliefs, in addition to the association of scarification with an increased risk of contracting hepatitis B and human immunodeficiency virus (HIV), are contemporary threats to this long-standing practice. Conclusions: Given the remarkably consistent appearance of scars that are described in the literature and depicted in images, scarification does not appear to be a random or accidental occurrence. Instead, it is a deliberate attempt to reproduce a custom that has been perfected after many years of practice in sub-Saharan Africa.

APA, Harvard, Vancouver, ISO, and other styles

9

NOGUEIRA, Isabel Roldo, Julio Cezar Uili COELHO, Micheli Fortunato DOMINGOS, Mônica Beatriz PAROLIN, Jorge Eduardo Fouto MATIAS, Alexandre Coutinho Teixeira de FREITAS, Eduardo Lopes MARTINS, and Marco Aurélio Raeder da COSTA. "GOOD QUALITY OF LIFE AFTER MORE THAN A DECADE OF LIVING DONOR LIVER TRANSPLANTATION." Arquivos de Gastroenterologia 58, no. 1 (March 2021): 10–16. http://dx.doi.org/10.1590/s0004-2803.202100000-04.

Full text

Abstract:

ABSTRACT BACKGROUND: Receptors of living donor liver transplantation (LDLT) have higher rate of postoperative biliary and vascular complications that may reduce posttransplant quality of life (QOL) due to the need of invasive and repetitive treatments. OBJECTIVE: The purpose of our study is to assess the various aspects of QOL of receptors undergoing LDLT after 10 years of transplantation and to identify potential factors that might be associated with impaired QOL. METHODS: Data of all patients with more than 10 years of LDLT were retrospectively evaluated. Patients were interviewed through a quality of life questionnaire (SF-36). RESULTS: From a total of 440 LT performed in 17 years (from September 1991 through December 2008), 78 patients underwent LDLT, of which 27 were alive and 25 answered completely the questionnaire. There were 17 (68%) men and 8 (32%) women, with a mean age of 38.6±18.5 years at the time of transplantation and mean follow up time of 15.1±1.9 years. The average MELD was 16.4±4.9 and the main indication for LT was hepatic cirrhosis caused by hepatitis B virus (32%). When compared to the general population, LDLT patients had lower mental health score (66.4 vs 74.5, P=0.0093) and higher vitality score (87.8 vs 71.9, P<0.001), functional aspects (94.6 vs 75.5, P=0.002), social aspects (93 vs 83.9, P=0.005), physical aspects (92 vs 77.5, P=0.006), and emotional aspects (97.33 vs 81.7, P<0.001). General health status (73.28 vs 70.2, P=0.074) and pain (78.72 vs 76.7, P=0.672) scores were similar in both groups. CONCLUSION: It is concluded that the various aspects LDLT recipients’ QOF are similar to those of the general population more than a decade after the transplant, except for the mental health domain which is lower.

APA, Harvard, Vancouver, ISO, and other styles

10

KRUGMAN, S. "Hepatitis B: Historical aspects." American Journal of Infection Control 17, no. 3 (June 1989): 165–67. http://dx.doi.org/10.1016/0196-6553(89)90211-3.

Full text

APA, Harvard, Vancouver, ISO, and other styles

11

Chen, Ping, Fen Zhang, Yiqun Shen, Yubo Cai, Chaolei Jin, Yan Li, Mingmin Tu, et al. "Health-Related Quality of Life and Its Influencing Factors in Patients with Hepatitis B: A Cross-Sectional Assessment in Southeastern China." Canadian Journal of Gastroenterology and Hepatology 2021 (July 7, 2021): 1–8. http://dx.doi.org/10.1155/2021/9937591.

Full text

Abstract:

Health-related quality of life (HRQoL) is an important aspect in the management of patients with hepatitis B (HB), which remains a serious health problem in China. There have been relatively few HRQoL studies involving Chinese patients with HB. The aim of this study was to analyze HRQoL in patients diagnosed with HB living in Zhejiang Province, China. A cross-sectional sample of 98 patients with chronic HB (CHB), 56 patients with advanced HB that have developed cirrhosis, and 48 healthy controls (HCs), all from Zhejiang Province, was used in this study. HRQoL was assessed using Short-Form 36 (SF-36) version 2, European quality of life questionnaire-5 dimensions (EQ-5D), and chronic liver disease questionnaire (CLDQ). Intergroup score differences were detected with U tests. Factors with a significant effect on HRQoL were identified with Spearman correlational analyses. Patients with HB (both groups) had lower SF-36 scores than HCs ( p < 0.01 ), with the exception of general health subscores. Patients with HB cirrhosis had the lowest scores in the EQ-5D visual analog scale (VAS) component. Furthermore, patients with HB cirrhosis had lower ( p < 0.01 ) CLDQ scores than patients with CHB. In our HB patient cohort, disease stage and income level were the factors most associated with HRQoL variables; age, education level, and marital status were, each, also significantly associated with some HRQoL variables in patients with HB in our study ( p < 0.05 or p < 0.01 ). HRQoL is diminished in patients with HB in southeastern China. Disease stage and income emerged as key determinants of HRQoL scores. Augmenting social and medical supports for patients with HB, especially those with a socioeconomic status and an advanced disease stage, may help to enhance HRQoL.

APA, Harvard, Vancouver, ISO, and other styles

12

Valaydon, Zina S., and Stephen A. Locarnini. "The virological aspects of hepatitis B." Best Practice & Research Clinical Gastroenterology 31, no. 3 (June 2017): 257–64. http://dx.doi.org/10.1016/j.bpg.2017.04.013.

Full text

APA, Harvard, Vancouver, ISO, and other styles

13

Wright, T. L., and J. Y. N. Lau. "Clinical aspects of hepatitis B virus infection." Lancet 342, no. 8883 (November 1993): 1340–44. http://dx.doi.org/10.1016/0140-6736(93)92250-w.

Full text

APA, Harvard, Vancouver, ISO, and other styles

14

BATE, R. G., and S. J. BOLLIPO. "Hepatitis B." Drug and Alcohol Review 15, no. 3 (September 1996): 289–305. http://dx.doi.org/10.1080/09595239600186031.

Full text

APA, Harvard, Vancouver, ISO, and other styles

15

Van Ditzhuijsen, T. J. M., and S. H. Yap. "Clinical Aspects of Hepatitis B Virus DNA Detection." Scandinavian Journal of Gastroenterology 24, sup171 (January 1989): 57–68. http://dx.doi.org/10.3109/00365528909091374.

Full text

APA, Harvard, Vancouver, ISO, and other styles

16

Anne Marie, COUROUCE, and BUSCH Michael. "Symposium S01 Hepatitis B and C - Biological aspects." Transfusion Clinique et Biologique 8 (June 2001): 7–8. http://dx.doi.org/10.1016/s1246-7820(01)00143-4.

Full text

APA, Harvard, Vancouver, ISO, and other styles

17

Notoatmojo, Harsoyo. "Immunological Aspects of Persistent Hepatitis B in Children." Paediatrica Indonesiana 38, no. 9-10 (July 11, 2017): 224. http://dx.doi.org/10.14238/pi38.9-10.1998.224-32.

Full text

Abstract:

We studied the immunological status of 203 children having persistent Hepatitis B (positive HBsAg) ranging in age from 6 to 14 years in Semarang Municipality. All patients showed negative results of humoral immunity (IgM anti-HBc), excluding the possibility of acute hepatitis B (HB). Cellular immunity examination using CMI skin test showed positive result in 64.9% of persistent and 65.2%, ln non-persistent HB (p>0.05). T cell examination shows significant statistical difference (p<0.01) between persistent and non-persistent HB, and there was a significant difference (p<0.01) on CD4 cell examination; indicating a difference on immunoregulation function and response repression of anti-virus between the two groups. There was no significant differences on CD4/CD8 ratio between persistent and non-persistent HB. The specific function of cytotoxic T cell also shows no significant difference between the two groups.

APA, Harvard, Vancouver, ISO, and other styles

18

Notoatmojo, Harsoyo. "Immunological aspects of persistent hepatitis B in children." Paediatrica Indonesiana 41, no. 4 (August 30, 2006): 208. http://dx.doi.org/10.14238/pi41.4.2001.208-13.

Full text

Abstract:

We studied the immunological status of 203 children having persistence Hepatitis B (positive HBsAg) ranging in age from 6 to 14 years in Semarang Municipality. The results of humoral immunity examination (IgM Anti-HBc) showed that all were negative, indicating that they are not in acute phase of hepatitis B infection. Cellular immunity examination, i.e., CMI skin test has shown positive result in 64.9% on persistent and 65.2% in non persistent hepatitis B (p>0.05). T cell examination showed statistically significant difference (p<0.01) between persistenct and non persistent hepatitis B patients, there was is also significant difference (p<0.01) on CD4 cell examination. These findings indicated that there was difference in immunoregulation function and response repression of antivirus between both groups of patients. On the other hand CD4/ CD8 ratio and T cell function showed no significant difference between the two gorups of patients; similarly the specific function of cytotoxic T cell was not significantly difference.

APA, Harvard, Vancouver, ISO, and other styles

19

Leblebicioglu, H. "Clinical Aspects of Chronic Hepatitis C Infection." JAMA: The Journal of the American Medical Association 290, no. 11 (September 17, 2003): 1453—a—1453. http://dx.doi.org/10.1001/jama.290.11.1453-b.

Full text

APA, Harvard, Vancouver, ISO, and other styles

20

Afzali, Majid, Hamidreza Naderi, and Masoud Mirzaei. "The epidemiological aspects of hepatitis B virus in Iran." Asian Pacific Journal of Tropical Disease 5, no. 7 (July 2015): 520–24. http://dx.doi.org/10.1016/s2222-1808(15)60828-3.

Full text

APA, Harvard, Vancouver, ISO, and other styles

21

Sharbaugh, Robert J. "Understanding viral hepatitis B." Home Care Provider 2, no. 4 (August 1997): 168–70. http://dx.doi.org/10.1016/s1084-628x(97)90065-4.

Full text

APA, Harvard, Vancouver, ISO, and other styles

22

Horváth, Gábor. "New drugs for the treatment of chronic hepatitis B and interdisciplinary aspects of chronic hepatitis B virus infection." Orvosi Hetilap 154, no. 29 (July 2013): 1142–50. http://dx.doi.org/10.1556/oh.2013.29625.

Full text

Abstract:

Hepatitis B virus infection is a significant health problem worldwide. The prevalence of HBsAg positivity is about 0.5–0.7% in Hungary. Liver cirrhosis and/or hepatocellular carcinoma develops in 15–40% of chronic hepatitis B virus infected patients without treatment. The ultimate goal of treatment would be to clear the virus from the infected subject; however, in practice, we can usually achieve long term suppression of viral replicaton with consequent prevention of the progression of liver disease, and reduction of the risk of the development of liver cirrhosis and hepatocellular carcinoma. Currently, there are two different treatment strategies for patients with chronic hepatitis B virus infection: therapy of finite duration with interferon or long-term treatment with nucleot(s)ide analogues. Entecavir and tenofovir are the two most effective nucleot(s)ide analogues with high barrier to resistance, thus, they can be confidently used as first-line treatments. Lamivudine engenders very high rates of resistance; adefovir is less efficacious than entecavir or tenofovir, and also engendering higher rates of resistance, thus none of them are recommended for initiation of a new treatment. Tenofovir is the treatment option in cases with lamivudine resistance, because entecavir has an unfavourable resistance-profile in this group of patients. Interferon is contraindicated during pregnancy. Should treatment of chronic hepatitis B virus infection be necessary during pregnancy, tenofovir, listed by the FDA as pregnancy category B drug, is to be preferred. Nucleot(s)ide analogues may be used to reduce the risk of intra-uterine and perinatal transmission of hepatitis B virus, which may occur in a proportion of newborns from highly viremic mothers, despite active and passive immunization. Similarly, tenofovir is recommended in the last trimester of pregnancy for women with high viremia. The risk of reactivation of chronic hepatitis B virus infection is high in HBsAg positive patients, and in patients with occult hepatitis B virus infection during and after chemotherapy or immunosuppressive treatment, including biological response modifiers (particularly related to rituximab therapy). Therefore, all candidates for these treatments should be screened for HBsAg and anti-HBc. Pre-emptive nucleot(s)ide analogues therapy should be initiated in patients with HBsAg positivity, and patients with occult hepatitis B virus infection. The role of general practitioners and occupational health physicians in the identification and the prevention of hepatitis B virus infection is stressed. Issues of high risk population groups, candidacy for vaccination, and methodology of active and passive immunisation are also reviewed in this paper. Orv. Hetil., 2013, 154, 1142–1150.

APA, Harvard, Vancouver, ISO, and other styles

23

Issaeva, N. "Hepatitis B and C: seroepidemiological aspects and modern prevention approach." Journal of Hepatology 34 (April 2001): 178. http://dx.doi.org/10.1016/s0168-8278(01)80653-x.

Full text

APA, Harvard, Vancouver, ISO, and other styles

24

Issaeva, N., A. Skovorodin, and O. Kanin. "Hepatitis B and C: seroepidemiological aspects and modern prevention approach." Journal of Hepatology 34 (April 2001): 178. http://dx.doi.org/10.1016/s0168-8278(01)81528-2.

Full text

APA, Harvard, Vancouver, ISO, and other styles

25

Rehermann, Barbara, and Michael P. Manns. "Immunologic aspects of acute and chronic hepatitis B and C." Current Opinion in Gastroenterology 12, no. 6 (November 1996): 554–59. http://dx.doi.org/10.1097/00001574-199611000-00011.

Full text

APA, Harvard, Vancouver, ISO, and other styles

26

Oon, C. ‐J, and W. N. Chen. "Current aspects of hepatitis B surface antigen mutants in Singapore." Journal of Viral Hepatitis 5, s2 (November 1998): 17–23. http://dx.doi.org/10.1046/j.1365-2893.1998.0050s2017.x.

Full text

APA, Harvard, Vancouver, ISO, and other styles

27

Shaw, T., and S. A. Locarnini. "Preclinical aspects of lamivudine and famciclovir against hepatitis B virus." Journal of Viral Hepatitis 6, no. 2 (March 1999): 89–106. http://dx.doi.org/10.1046/j.1365-2893.1999.00151.x.

Full text

APA, Harvard, Vancouver, ISO, and other styles

28

Bobinski, Mary Anne. "Health Care–Associated Hepatitis B and C Viruses: Legal Aspects." Clinics in Liver Disease 14, no. 1 (February 2010): 105–17. http://dx.doi.org/10.1016/j.cld.2009.11.002.

Full text

APA, Harvard, Vancouver, ISO, and other styles

29

Kondo, Yasuteru, Masashi Ninomiya, Eiji Kakazu, Osamu Kimura, and Tooru Shimosegawa. "Hepatitis B Surface Antigen Could Contribute to the Immunopathogenesis of Hepatitis B Virus Infection." ISRN Gastroenterology 2013 (January 16, 2013): 1–8. http://dx.doi.org/10.1155/2013/935295.

Full text

Abstract:

Various findings concerning the clinical significance of quantitative changes in hepatitis B surface antigen (HBsAg) during the acute and chronic phase of hepatitis B virus (HBV) infection have been reported. In addition to being a biomarker of HBV-replication activity, it has been reported that HBsAg could contribute to the immunopathogenesis of HBV persistent infection. Moreover, HBsAg could become an attractive target for immune therapy, since the cellular and humeral immune response against HBsAg might be able to control the HBV replication and life cycle. However, several reports have described the immune suppressive function of HBsAg. HBsAg might suppress monocytes, dendritic cells (DCs), natural killer (NK), and natural killer T (NK-T) cells by direct interaction. On the other hand, cytotoxic T lymphocytes (CTLs) and helper T (Th) cells were exhausted by high amounts of HBsAg. In this paper, we focused on the immunological aspects of HBsAg, since better understanding of the interaction between HBsAg and immune cells could contribute to the development of an immune therapy as well as a biomarker of the state of HBV persistent infection.

APA, Harvard, Vancouver, ISO, and other styles

30

Martins, Reinaldo Menezes, and Maria de Lourdes de Souza Maia. "Eventos adversos pós-vacinais e resposta social." História, Ciências, Saúde-Manguinhos 10, suppl 2 (2003): 807–25. http://dx.doi.org/10.1590/s0104-59702003000500018.

Full text

Abstract:

A grande maioria das polêmicas públicas relativas a hipotéticos malefícios provocados pelas vacinas é extensão de controvérsias e discussões que surgem no próprio meio médico. Exemplos são os malefícios do mercúrio contido em várias vacinas, como a tríplice viral (MMR), provocando doença inflamatória intestinal e autismo; a vacina contra hepatite B e esclerose múltipla; o vírus SV40 em vacinas contra poliomielite e câncer; a transcriptase reversa em células de embrião de pinto e riscos de infecção por retrovírus; vacinas como causa de asma, diabetes insulino-dependente. Em algumas situações houve nítido prejuízo para a saúde da população, como aconteceu na Inglaterra após noticiários alarmantes sobre os riscos da vacina tríplice DTP na década de 1970 e, mais recentemente, com a vacina tríplice viral, contra sarampo, caxumba e rubéola, também na Inglaterra, e a vacina contra hepatite B, na França. Além disso, grupos ativistas contrários à vacina veiculam notícias alarmantes através dos meios de comunicação, especialmente pela Internet. Beneficiam-se dessa situação pessoas e advogados que, com ou sem fundamento científico para as suas alegações, buscam indenizações milionárias, o que tem causado malefícios para a população, principalmente em países como os Estados Unidos, pelo aumento no custo das vacinas, para fazer frente aos processos judiciais, e pela desistência de produção por várias empresas, contribuindo para crises de disponibilidade das vacinas. O Programa Nacional de Imunizações do Brasil tem tido êxito em lidar com os aspectos públicos dos eventos adversos, através da capacitação dos profissionais de saúde que atuam no setor, tanto nos aspectos técnicos como na comunicação social.

APA, Harvard, Vancouver, ISO, and other styles

31

Silva, L. C. da, F. J. Carrilho, A. Di Pietro, A. Boris-Chavez, P. Albornoz, H. Sette Jr., C. F. F. Franco, R. Antonelli, and A. Saez-Alquézar. "Epidemiological aspects of acute viral hepatitis in São Paulo, Brazil." Revista do Instituto de Medicina Tropical de São Paulo 28, no. 6 (December 1986): 400–405. http://dx.doi.org/10.1590/s0036-46651986000600004.

Full text

Abstract:

As few reports on the prevalence of each type of viral hepatitis have been published in our country, we studied 154 patients with acute viral hepatitis consecutively seen at the Liver Unit from November 1980 to November 1984. The frequency of hepatitis A, B and non-A, non-B was 52.6%, 27.3% and 20.1% respectively. Greater frequency in young people, previous contact with infected patients and ingestion of suspected foods were the predominant epidemiological features in the hepatitis A group. Hepatitis B was characterized by the parenteral, non-transfusional exposure, previous contact and a high occurence in health-care workers. A history of blood transfusion was a significant finding in the hepatitis non-A, non-B group. Finally, the routes of transmission were unknown in 30-40% of the three groups of patients.

APA, Harvard, Vancouver, ISO, and other styles

32

Haque, Md Azizul, M. Harun Or Rashid, M. Abdul Alim, MMR Khan, I. Mahmood, and Md Zahirul Haque. "Occult Hepatitis B : A Hidden Threat." TAJ: Journal of Teachers Association 23, no. 1 (June 1, 2010): 109–13. http://dx.doi.org/10.3329/taj.v23i1.41153.

Full text

Abstract:

Occult hepatitis B (OHB) is defined as the presence of HBV-DNA in liver with or without detectable HBV DNA in serum in patients who are HBsAg negative in currently available assays. Diagnosis of occult HBV infections requires sensitive HBV-DNA PCR assay. Though reports of occult hepatitis B infections are coming from almost every corner of the world, the exact prevalence of this hidden menace is still not know. Several aspects of occult hepatitis B infection are still not resolved including its clinical significance relating to the molecular basis, risk of transmission, reactivation and progression to chronic liver disease. In this review article, we will try to explore the current concepts and clinical implications of occult hepatitis B virus infection. TAJ 2010; 23(1): 109-113

APA, Harvard, Vancouver, ISO, and other styles

33

Enaleeva, D. Sh. "Modern aspects of the natural course of chronic viral hepatitis B." Kazan medical journal 93, no. 2 (April 15, 2012): 161–66. http://dx.doi.org/10.17816/kmj2279.

Full text

Abstract:

Currently there are about 400 million people infected with the hepatitis B virus, including five million people - in Russia. A serious problem is the development of complications of chronic viral hepatitis’ - liver cirrhosis and hepatocellular carcinoma, from which eventually 20-35% of patients die. Undoubtedly, the outstanding science achievement of the XX century was the creation of a genetically engineered vaccine against hepatitis B. The pursued immunizations on a global scale has led to significant results - reduction of the number of cases of acute forms of viral hepatitis B, the frequency of formation of the chronic variant of the disease. Despite these successes, there remains the problem of prevention of the perinatal transmission path. Identified were the risk factors for neonatal infection, amongst which the most significant are the presence of the antigen of the hepatitis B virus, which is not a part of the Dane particles (HBEAg), and the level of viremia prior to delivery. The basis of prevention is an active-passive immunization, which helps prevent infection in infants in 90-95% of cases. Encouraging results (reduction in the risk of infant infection) were obtained in studies of antiviral therapy in the III trimester of pregnancy. The introduction of new molecular biological diagnostic methods (polymerase chain reaction) made it possible to determine the genetic material of the virus in serum and tissues, the presence of mutations and genetic variability of the virus. At present, identified are the factors that determine the progression of the disease, the efficacy of antiviral therapy. Identified are the new variants of the clinical course of viral hepatitis B, depending on the profile of the serological (antigen-antibody) markers. The latent course of viral hepatitis B deserves special attention. The serological feature of this variant is the presence of «isolated» antibodies and/or deoxyribonucleic acid of the virus, or the absence of all markers of hepatitis B. It is obvious that patients with a latent course of infection pose a real threat in spreading viral hepatitis B.

APA, Harvard, Vancouver, ISO, and other styles

34

Jia-Horng, Kao, Chen Pei-Jer, Lai Ming-Yang, and Chen Ding-Shinn. "Clinical and virological aspects of hepatitis B genotype B and C-infected blood donors." Journal of Hepatology 36 (April 2002): 114. http://dx.doi.org/10.1016/s0168-8278(02)80403-2.

Full text

APA, Harvard, Vancouver, ISO, and other styles

35

Rehermann, Barbara, and Antonio Bertoletti. "Immunological aspects of antiviral therapy of chronic hepatitis B virus and hepatitis C virus infections." Hepatology 61, no. 2 (January 20, 2015): 712–21. http://dx.doi.org/10.1002/hep.27323.

Full text

APA, Harvard, Vancouver, ISO, and other styles

36

Rogler, Charles E., Okio Hino, and Chun-Yeh Su. "Molecular aspects of persistent woodchuck hepatitis virus and hepatitis B virus infection and hepatocellular carcinoma." Hepatology 7, S1 (January 1987): 74S—78S. http://dx.doi.org/10.1002/hep.1840070713.

Full text

APA, Harvard, Vancouver, ISO, and other styles

37

Kristian, Pavol, Zuzana Dankulincová Veselská, Zuzana Paraličová, Peter Jarčuška, Ladislav Virág, Ivana Valková, and Ivan Schréter. "Regional and Ethnic Aspects of Viral Hepatitis B among Pregnant Women." Central European Journal of Public Health 21, no. 1 (March 1, 2013): 22–25. http://dx.doi.org/10.21101/cejph.a3800.

Full text

APA, Harvard, Vancouver, ISO, and other styles

38

Kryger, Peter. "Non-A, non-B hepatitis. Serological, clinical, morphological and prognostic aspects." Liver 3, no. 3 (December 10, 2008): 176–98. http://dx.doi.org/10.1111/j.1600-0676.1983.tb00866.x.

Full text

APA, Harvard, Vancouver, ISO, and other styles

39

Hess, G. "Virological and serological aspects of hepatitis B and the delta agent." Gut 34, no. 2 Suppl (January 1, 1993): S1—S5. http://dx.doi.org/10.1136/gut.34.2_suppl.s1.

Full text

APA, Harvard, Vancouver, ISO, and other styles

40

Ryu, Wang-Shick. "Molecular Aspects of Hepatitis B Viral Infection and the Viral Carcinogenesis." BMB Reports 36, no. 1 (January 31, 2003): 138–43. http://dx.doi.org/10.5483/bmbrep.2003.36.1.138.

Full text

APA, Harvard, Vancouver, ISO, and other styles

41

Intonazzo, V., G. La Rosa, M. F. Massenti, A. M. Perna, E. Restivo, A. Sferlazzo, and L. Dardanoni. "Epidemiological aspects of hepatitis B in palermo: Changes in HBV spread." European Journal of Epidemiology 7, no. 6 (November 1991): 696–98. http://dx.doi.org/10.1007/bf00218685.

Full text

APA, Harvard, Vancouver, ISO, and other styles

42

Tagar, Muhammad Paryal, Mujeeb Rehman Abbasi, Mohammad Rafique Pathan, and Hafeezullah Shaikh. "HEPATITIS B & C;." Professional Medical Journal 24, no. 02 (February 14, 2017): 278–81. http://dx.doi.org/10.29309/tpmj/2017.24.02.508.

Full text

Abstract:

Objectives: To determine the frequency of hepatitis b & c viral infection insurgical patients. Study Design: Descriptive case series. Place and Duration of Study: Thisstudy was conducted at surgical department of multiple hospitals and compares the results,JPMC Karachi, Civil Hospital Naushahro Feroze and Jamshoro, Pakistan from August 2014 toDecember 2015. Methodology: All 2645 patients were admitted for emergency and electivesurgery. All patients taken detail history regarding demographic parameter and risk factorslike previous surgery, blood transfusion, barbar, Road Traffic accident, haemodialysis, Tattoos/body piercing, injecting drug user, family history of hepatitis, previous history of jaundiceand Hospitalization. Hospital laboratory was used for screened HBsAg and Anti HCV usingimmunochromatography (ICT method). Patients excluded who were those did not need thesurgery or known case of HBsAg and Anti HCV. Data collected was entered into and analyzedby using statistical package for the social science – 20. Results: Out of 2645 patients, maleto female ratio were 1.9:1. The mean age was 40.2+6.12years (20 to 60 years). Out of 2645patients, Anti HCV was positive in 288(10.88%) cases followed by HBsAg was in 152(5.74%)cases. While both positive in 36 (1.36%) cases. We observed Previous surgery was main riskfactor in the reactive 156(32.77%) cases followed by Barbar, Blood transfusion were 74(15.54%)and 47(9.87%) respectively. Conclusion: We conclude that preoperatively screening of hepatitisB and C should be performed.

APA, Harvard, Vancouver, ISO, and other styles

43

Vickery, Karen. "Duck hepatitis B virus: a model for assessing the efficacy of disenfectants against human hepatitis B virus infection." Microbiology Australia 31, no. 4 (2010): 171. http://dx.doi.org/10.1071/ma10171.

Full text

Abstract:

One of the most important aspects of infection control is the interruption of transmission of infectious organisms to and from patients within the hospital environment. Of particular concern are the blood-borne viruses HIV, hepatitis B virus (HBV) and hepatitis C virus (HCV). Disinfectants play an important role in infection control, but their virucidal efficacy is difficult to measure in vitro because of the high susceptibility of tissue culture systems to damage by chemical agents and the relatively low titres which are achieved in growing many important viruses. Additionally, HBV is almost uncultivable in vitro and fails to infect more common laboratory animals. Therefore, the duck model of HBV infection has been used for testing disinfectant action against HBV.

APA, Harvard, Vancouver, ISO, and other styles

44

Boroń, P., Anna Boroń-Kaczmarska, Elźbieta Bobrowska, W. Lapinśki, and Hanna Kaminska. "Epidemiological aspects of viral hepatitis B and delta-hepatitis in selected population from białystok district, Poland." Infection 17, no. 3 (May 1989): 175–76. http://dx.doi.org/10.1007/bf01644025.

Full text

APA, Harvard, Vancouver, ISO, and other styles

45

Avdeeva, M. G., V. N. Gorodin, M. I. Kulbuzheva, L. P. Blazhnaya, S. R. Hasnudinova, and E. I. Kolodko. "Chronic viral mixt-hepatitis: current clinical and epidemiological aspects." Epidemiology and Infectious Diseases 20, no. 6 (December 15, 2015): 19–25. http://dx.doi.org/10.17816/eid40876.

Full text

Abstract:

Objective: Improvement of the diagnosis and prognosis of liver disease of viral etiology based on the analysis of clinical and epidemiological characteristics of the course and outcome of viral mixt-hepatitis. Materials and methods There are presented results of the retrospective study of 106 patients with chronic viral mixt-hepatitis (study group), which were under the medical observation for a period from two to five years between 2010 and 2014. The comparison group was consisted of 1,913 patients with chronic hepatitis C. Results and discussion The morbidity of chronic viral mixt-hepatitis in the majority of cases is registered among socially active groups of young and middle age persons, more common among males. Frequent risk factors are the artificial factor (55%), the intravenous drug usage (25%), tattooing (19%). Typical concomitant illnesses are diseases of the gastrointestinal tract and the endocrine system. Chronic viral mixt-hepatitis is mainly caused by a combination of HCV and HBV, and HCV + HBV + HDV also. HCV replication is noted in 64% of cases, the replication of HBV - in 58%, HDV replication - in 20%. Transformation into cirrhosis in patients with mixt-hepatitis C+B+D was recorded in 25% of cases, in mixt-hepatitis C+B cases - in 7.1%. In the group of C+B+D hepatitis patients, viral replication of HBV and HDV without HCV replication transformation into cirrhosis was seen in 36%. In the case of HDV replication alone, the rate of cirrhosis was 25%, while in cases with isolated HBV replication - 14%. In patients with mixt-infection C+B, the development of cirrhosis was registered within subgroup with simultaneous replication of HBV and HCV viruses in 9% cases. An isolated HCV replication, in general was less often, and led to the transformation into cirrhosis in 6% cases. Conclusions. Simultaneous replication of more than one type of hepatitis virus promotes transformation into cirrhosis, in greater extent, simultaneous replication of HBV + HDV, and monoreplication of HDV virus also. In order to prevent further progression of the pathological process it is recommended the well-timed causal treatment order with account for the predominant virus replication.

APA, Harvard, Vancouver, ISO, and other styles

46

McCombie, S. C. "Dealing with AIDS: Lessons from Hepatitis B." Medical Anthropology 10, no. 2-3 (March 1989): 151–57. http://dx.doi.org/10.1080/01459740.1989.9965960.

Full text

APA, Harvard, Vancouver, ISO, and other styles

47

Stephenne, J. "Development and production aspects of a recombinant yeast-derived hepatitis B vaccine." Vaccine 8 (March 1990): S69—S73. http://dx.doi.org/10.1016/0264-410x(90)90221-7.

Full text

APA, Harvard, Vancouver, ISO, and other styles

48

Kelder, M. J., A. P. Nauta, M. J. Horsten, and J. Dam. "Hepatitis B vaccinatie altijd verplicht?RisicofactorenVaccinatie." Tijdschrift voor Bedrijfs- en Verzekeringsgeneeskunde 8, no. 7 (July 2000): 28. http://dx.doi.org/10.1007/bf03073610.

Full text

APA, Harvard, Vancouver, ISO, and other styles

49

. "Veelbelovend nieuw geneesmiddel tegen Hepatitis B." Tijdschrift voor Bedrijfs- en Verzekeringsgeneeskunde 14, no. 3 (March 2006): 160. http://dx.doi.org/10.1007/bf03074350.

Full text

APA, Harvard, Vancouver, ISO, and other styles

50

Marullo, Susan Shirey. "Hepatitis B: An Urban Epidemic." Home Healthcare Nurse: The Journal for the Home Care and Hospice Professional 4, no. 4 (July 1986): 18–23. http://dx.doi.org/10.1097/00004045-198607000-00003.

Full text

APA, Harvard, Vancouver, ISO, and other styles

We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!